The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. Insiders have been net buyers over the past quarter.
OneMedNet Corp
ONMD · NASDAQ · USD · Market cap $39M · 22 employees
OneMedNet Corporation, a healthcare software company, provides digital medical image management, exchange, and sharing solutions in the Americas, Europe, and the Middle East.
FAIL · Does not pass the screenAt the last full screen
2025-12-31
Screened 2025-12-31 · the tape above runs as of 15:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markdown label.
OneMedNet Corp holds its Markdown at $0.68. The statistical read favours the sellers, held for 47 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the sellers, held for 47 days |
| Price at the screen | $0.68 |
| Valuation | N/A trailing · N/A forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.14 |
Five Screens, Shown in Full
Does not pass. Accounts receivable
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 26.50% | Below 33% | Interest-bearing debt is just 26.5% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 23.52% | Below 33% | Cash held in interest-bearing accounts and securities is 23.5% of assets, under the one-third limit. | Pass |
| Receivables | 50.21% | Below 49% | Money owed to the company is 50.2% of assets, above the 49% limit. | Fail |
| Revenue purity | 0.00% | Below 5% | Only 0.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Business, in Plain Words| EPS, trailing | -0.04 |
| Revenue growth | -29.9%revenue is shrinking |
| Profit margin | -254.3%currently unprofitable |
| FCF yield | -24.92% |
| Current ratio | 0.27below 1: short-term bills exceed liquid assets |
| Beta | 1.14moves a little more than the market |
| Short interest, float | 0.01% |
| 52-week range | 0.44 - 4.22 |
| Moat | NONE |
| Market cap | $39M |
| Employees | 22 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeONMD trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 25.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Yu Jeffrey | Chief Medical Officer, 10% | P - Purchase | 142,857 | $90,000 |
| 2026-07-30 | Kosasa Thomas | Dir, 10% | P - Purchase | 1,449,275 | $1,000,000 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $0.98 | -39.2% | · | $608 | -39.2% |
| 2 months | $0.83 | -28.3% | · | $717 | -28.3% |
| 3 months | $0.78 | -24.0% | · | $760 | -24.0% |
| 6 months | $1.59 | -62.5% | · | $375 | -62.5% |
| 1 year | $0.44 | +37.0% | · | $1,370 | +37.0% |
| 2 years | $1.41 | -57.7% | · | $423 | -57.7% |
| 3 years | $10.90 | -94.5% | · | $55 | -94.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ONMD does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.